国浩律师（杭州）事务所 关 于 浙江东方基因生物制品股份有限公司 2025 年第一次临时股东大会 法律意见书 地址：杭州市上城区老复兴路白塔公园 B 区 2 号、15 号国浩律师楼 邮编：310008 Grandall Building, No.2＆No.15, Block B, Baita Park, Old Fuxing Road, Hangzhou, Zhejiang 310008, China 电话/Tel: (+86)(571) 8577 5888 传真/Fax: (+86)(571) 8577 5643 电子邮箱/Mail：grandallhz@grandall.com.cn 法律意见书 致：浙江东方基因生物制品股份有限公司 国浩律师（杭州）事务所（以下简称"本所"）接受浙江东方基因生物制品 股份有限公司（以下简称"公司"）委托，指派律师出席公司 2025 年第一次临 时股东大会（以下简称"本次股东大会"），并依据《中华人民共和国公司法》 （以下简称"《公司法》"）、《中华人民共和国证券法》（以下简称"《证券 法》"）、中国证券监督管理委员会（以下简称"中国证监会"）发布的《上市 公司股东会规则》 ...

（文章来源：每日经济新闻） 每经AI快讯，Wind数据显示，9月12日，4家上市公司回购股票，其中东方生物回购金额最高达2211万 元，回购数量82万股，长城汽车回购金额达1353万元，回购数量108万股，千味央厨回购金额达372万 元，回购数量11万股。 ...

Wind数据显示，9月12日，4家上市公司回购股票，其中东方生物回购金额最高达2211万元，回购数量 82万股，长城汽车回购金额达1353万元，回购数量108万股，千味央厨回购金额达372万元，回购数量11 万股。 ...

Core Viewpoint - Oriental Bio has faced significant operational challenges, including two consecutive years of losses and recent management changes, which have raised concerns about its future performance and strategic direction [1][2][3]. Financial Performance - Oriental Bio reported a dramatic decline in revenue, with 2023 revenue plummeting by 90.65% to 820 million yuan, and a net loss of 398 million yuan, marking a 119.23% year-over-year decrease [3][4]. - In 2021, the company achieved record revenues of 10.169 billion yuan, a 211.43% increase from the previous year, and a net profit of 4.92 billion yuan, reflecting a 193.33% growth [3]. - The company’s performance was heavily influenced by its COVID-19 testing products, which contributed significantly to its revenue during the pandemic [4]. Management Changes - The company has experienced a shift in its management team, with two board members resigning within a month, raising questions about leadership stability [1]. Business Expansion and Strategy - Oriental Bio is actively expanding its business, particularly in the U.S. market, through acquisitions and the establishment of production bases for chronic disease monitoring and animal diagnostics [5][6]. - The company has diversified its portfolio by adding an animal vaccine business, aiming to create a dual-track business model that includes both human and animal health [5]. Legal Challenges - The company is currently facing a significant lawsuit in the U.S., with claims exceeding 1 billion USD related to alleged contract violations, which could impact its financial stability [6]. Shareholder Actions - In response to ongoing losses and to bolster market confidence, Oriental Bio initiated a share buyback program, committing to repurchase shares worth between 25 million and 50 million yuan [7].

Core Viewpoint - On September 11, Oriental Bio held a performance briefing for the first half of 2025, highlighting its focus on expanding its animal health products, particularly vaccines and diagnostic reagents, in both domestic and European-American markets [1] Company Summary - The management indicated that the company is accelerating the registration of products in the domestic and European-American markets based on existing certified products [1]

Group 1 - The company announced the completion of a share buyback on September 11, 2025, having repurchased 1,801,328 shares [1] - The repurchased shares represent 0.8935% of the company's total share capital of 201,600,000 shares [1]

格隆汇9月11日丨东方生物(688298.SH)公布，2025年9月11日，公司完成回购，已实际回购公司股份 1,801,328股，占公司总股本201,600,000.00股的比例为0.8935%，回购最低价格26.45元/股，回购最高价 格29.52元/股，回购均价27.75元/股，使用资金总额4,999.4277万元（不含印花税、交易佣金等交易费 用）。 ...

证券代码：688298 证券简称：东方生物 公告编号：2025-050 浙江东方基因生物制品股份有限公司 关于股份回购实施结果暨股份变动的公告 （四）本次回购使用的资金为公司自有资金及股票回购专项贷款资金，不会 对公司的经营、盈利能力和未来发展产生重大影响，不会导致公司控制权发生变 化，回购后公司的股权分布情况符合上市公司的条件，不会影响公司的上市地位。 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： | 回购方案首次披露日 | 2025/6/28 | | | | | --- | --- | --- | --- | --- | | 回购方案实施期限 | 2025 6 26 日~2025 年 月 25 | 年 | 月 | 9 日 | | 预计回购金额 | 2,500万元~5,000万元 | | | | | 回购价格上限 | 32.44元/股 | | | | | 回购用途 | □减少注册资本 □用于员工持股计划或股权激励 | | | | | | □用于转换公司可转债 | | | | | | √为维护公司价值及股东权 ...

Group 1 - The company has completed a share buyback, repurchasing 1.8013 million shares, which accounts for 0.8935% of the total share capital [1] - The buyback price ranged from 26.45 yuan per share to 29.52 yuan per share, with a total expenditure of 49.9943 million yuan [1] - The repurchased shares will be used to maintain the company's value and protect shareholder interests, and will be sold through centralized bidding 12 months after the announcement of the buyback results [1]

Market Performance - The pharmaceutical sector experienced a decline of -1.91% on September 9, 2025, underperforming the CSI 300 index by 1.21 percentage points, ranking 28th among 31 sub-industries in the Shenwan classification [1] - Among sub-industries, pharmaceutical distribution (-0.52%), blood products (-0.62%), and in vitro diagnostics (-0.73%) performed relatively better, while medical R&D outsourcing (-3.63%), medical devices (-2.47%), and medical consumables (-2.06%) lagged behind [1] - Top three gainers included Rongchang Bio (+11.92%), Hehua Co. (+10.07%), and Zhend Medical (+10.00%), while the largest decliners were Yifang Bio (-11.74%), Huahai Pharmaceutical (-10.00%), and Chenxin Pharmaceutical (-8.42%) [1] Industry News - BMS announced positive results from the Phase II clinical trial of Pumitamig, a bispecific antibody developed in collaboration with BioNTech for the treatment of extensive-stage small cell lung cancer (ES-SCLC), showing a confirmed objective response rate (cORR) of 76.3% and a disease control rate (DCR) of 100% [2] - Pumitamig targets PD-L1 and VEGF-A, designed to restore the function of effector T cells in the tumor microenvironment while locally neutralizing the effects of VEGF-A [2] Company News - Heng Rui Medicine (600276) announced that its subsidiary Chengdu Shengdi Pharmaceutical received approval from the National Medical Products Administration for its product, Eicosapentaenoic Acid Ethyl Ester Soft Capsules, to lower triglyceride levels in adult patients with severe hypertriglyceridemia (≥500 mg/dL) [3] - Taiji Group (600129) reported that its subsidiary Fuling Pharmaceutical Factory received a clinical trial approval notice for Semaglutide injection for the treatment of type 2 diabetes [3] - Huahai Pharmaceutical (600521) disclosed that its subsidiary Huahai Jiancheng underwent a pre-approval inspection by the FDA from July 14 to 18, 2025, covering the overall quality management system and the active pharmaceutical ingredient Gabapentin, which met the CGMP requirements [3] - Dongfang Bio (688298) announced that its subsidiary Laihe Bio obtained a Class III medical device registration certificate for its influenza virus antigen detection kit (colloidal gold method), enhancing the company's product portfolio in the respiratory joint detection field [3]